Desmopressin testing in children with von Willebrand syndrome in haemostaseologic centers of Saxonia, Saxonia-Anhalt and Thuringia;Desmopressin-Tests bei Kindern mit von-Willebrand-Syndrom in den Gerinnungszentren Sachsens, Sachsen-Anhalts und Thüringens

Hamostaseologie

Volumn 29, Issue SUPPL1, 2009, Pages

  Huhn, B ^a   Hofmann, A ^b   Hofmann, K ^b   Sirb, H ^c   Aumann, V ^d   Kentouche, K ^e   Sauerbrey, A ^f   Franke, D ^g   Kuhlisch, E ^a   Knofler R ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b KLINIKUM CHEMNITZ   (Germany)

^c DRK Krankenhaus Lichtenstein   (Germany)

^d UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^e FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^f HELIOS KLINIKUM ERFURT   (Germany)

^g Praxis für Innere Medizin und Gefäßkrankheiten Magdeburg   (Germany)

Author keywords

Children; Desmopressin testing; Von Willebrand syndrome

Indexed keywords

ARGIPRESSIN[1 DEAMINO]; HEMOSTATIC AGENT;

ADOLESCENT; ARTICLE; CHILD; DRUG EFFECT; FEMALE; GERMANY; HEMOSTASIS; HUMAN; INFANT; INFUSION PUMP; INTRANASAL DRUG ADMINISTRATION; MALE; PRESCHOOL CHILD; RETROSPECTIVE STUDY; TIME; VON WILLEBRAND DISEASE;

ADMINISTRATION, INTRANASAL; ADOLESCENT; CHILD; CHILD, PRESCHOOL; DEAMINO ARGININE VASOPRESSIN; FEMALE; GERMANY; HEMOSTASIS; HEMOSTATICS; HUMANS; INFANT; INFUSION PUMPS; MALE; RETROSPECTIVE STUDIES; TIME FACTORS; VON WILLEBRAND DISEASES;

EID: 75549083887     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1621610     Document Type: Article

References (15)

1. Allen GC, Armfield DR, Bontempo FA et al. Adenotonsillectomy in children with von Willebrand disease. Arch Otolaryngol Head Neck Surg 1999; 125: 547-551.
2. Castaman G, Lethagen S, Federici AB et al. Response to Desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood 2008; 111: 3531-3539.
3. Favaloro EJ. Laboratory monitoring of therapy in von Willebrand disease: efficacy of the PFA-100® and von Willebrand factor collagen-binding activity as coupled strategies. Sem Thromb Hemost 2006; 32: 566-576.
4. Federici AB. The use of Desmopressin in von Willebrand disease: the experience of the first 30 years (1977-2007). Haemophilia 2008; 14: 5-14.
5. Federici AB, Castaman G, Thompson A et al. Von Willebrand's disease: clinical management. Haemophilia 2006; 12: 152-158.
6. Gill JC, Ottum M, Schwartz B et al. Evaluation of high concentration intranasal and intravenous desmopressin in pediatric patients with mild hemophilia A or mild-to-moderate type 1 von Willebrand disease. J Pediatr 2002; 140: 595-599.
7. Hanebutt FL, Rolf N, Loesel A et al. Evaluation of desmopressin effects on haemostasis in children with congenital bleeding disorders. Haemophilia 2008; 14: 524-530.
8. Kaufmann JE, Vischer UM. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J Thromb Haemost 2003; 1: 682-689.
9. Mannucci PM, Pareti FI, Holmberg L et al. Studies on the prolonged bleeding time in von Willebrand's disease. J Lab Clin Med 1976; 88: 662-671.
10. Michiels JJ, van Vliet HH, Berneman Z et al. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients with von Willebrand disease type 1, 2 and 3. Clin Appl Thromb Hemost 2007; 13: 14-34.
11. Miesbach W, Duck O, Krekeler S et al. Evaluation of prospective criteria for the clinical assessment of efficacy and safety of DDAVP. Hamostaseologie 2009; 29: PP3.2-10.
12. Miesbach W, Dück O, Llugaliu B et al. Verträglichkeit und Wirksamkeit von DDAVP. Hämostaseologie 2008; 28: 112.
13. Nolan B, White B, Smith J et al. Desmopressin: therapeutic limitations in children and adults with inherited coagulation disorders. Br J Haematol 2000; 109: 865-869.
14. Schneppenheim R, Budde U. Angeborenes und erworbenes von-Willebrand-Syndrom. Hamostaseologie 2008; 28: 312-319.
15. Sutor AH. DDAVP is not a panacea for children with bleeding disorders. Br J Haematol 2000; 108: 217-227.